Purpose. To evaluate retinal functional improvement by means of visual acuity and retinal sensibility examination after intravitreal\ndexamethasone implant in patients affected by cystoid macular edema secondary to retinal vein occlusion. Methods. Twenty-six\nconsecutive patients affected by retinal vein occlusion complicated by cystoid macular edema were enrolled in this prospective\ninterventional study. All patients underwent a baseline complete ophthalmological evaluation as well as retinal angiography, OCT\nexamination, and microperimetry evaluation. Each patient was treated with intravitreal injection of a long-term steroid implant\n(Ozurdex, Allergan). Follow-up evaluations were performed at months 1, 3, and 6 and completed by OCT and MP1 examination.\nClinical data underwent statistical analysis. Results. Baseline functional evaluation showedmean visual acuity of 0,63±0,42 LogMAR\nand retinal sensitivity of 7,93±4,73 dB (mean±standard deviation); after treatment, at day 30 we found, respectively, 0,43±0,38\nLogMAR (p<0.05, compared to baseline) and 10,15±4,410 dB (p<0.05); at day 90, we found 0,44±0,32 (p<0.05) and 9.61±4,29 dB\n(p<0.05); at day 180, we found 0,41±0,31 (p<0.05) and 9,95±3,79 dB (p<0.05). Fixation pattern improved significantly (p<0.05),\nshowing a stable fixation in 30% of patients at baseline, increasing to 77% of patients at day 180. Baseline morphological evaluation\nshowed a central retinal thickness (CRT) of 398,21±181,65 ... after treatment; we found a CRT of 222,64±95,21 ... at day 30\n(p<0.05, compared to baseline), 307,50±120,25 ... (p<0.05) at day 90, and 294,93±135,86 ... (p<0.05) at day 180. About 15,3%\npatients showed already atmonth 3 a recurrence ofmacular edema.They underwent a retreatment beforemonth 6 as for treatment\nguidelines. Conclusion. Our detailed analysis showed the significative increase in retinal function in the early phases of the followup.\nRetinal sensibility showed a stronger correlation than VA in macular edema reabsorption, better underlying the progressive\nfunctional recovery and increase in quality of vision and life for the patients. This trial is registered with ClinicalTrials.gov\nNCT03559491.
Loading....